Collectively, aberrant lipid metabolism is a key driver of MDSC-mediated immunosuppression, and metabolic targets such as CD36, FATP2, COX-2, β2-AR, and LOX-1 represent promising strategies for cancer therapy. Here, CD36 is linked to cancer.